Look Up > Drugs > Nedocromil Sodium
Nedocromil Sodium
Pronunciation
U.S. Brand Names
Generic Available
Canadian Brand Names
Pharmacological Index
Use
Pregnancy Risk Factor
Contraindications
Warnings/Precautions
Adverse Reactions
Stability
Mechanism of Action
Pharmacodynamics/Kinetics
Usual Dosage
Mental Health: Effects on Mental Status
Mental Health: Effects on Psychiatric Treatment
Dental Health: Local Anesthetic/Vasoconstrictor Precautions
Dental Health: Effects on Dental Treatment
Patient Information
Nursing Implications
Dosage Forms

Pronunciation
(ne doe KROE mil SOW dee um)

U.S. Brand Names
Alocril™; Tilade® Inhalation Aerosol

Generic Available

No


Canadian Brand Names
Mireze®

Pharmacological Index

Antihistamine, Inhalation


Use

Maintenance therapy in patients with mild to moderate bronchial asthma


Pregnancy Risk Factor

B


Contraindications

Hypersensitivity to nedocromil or other ingredients in the preparation


Warnings/Precautions

Safety and efficacy in children <12 years of age have not been established; if systemic or inhaled steroid therapy is at all reduced, monitor patients carefully; nedocromil is not a bronchodilator and, therefore, should not be used for reversal of acute bronchospasm


Adverse Reactions

Aerosol: 1% to 10%:

Cardiovascular: Chest pain

Central nervous system: Dizziness, dysphonia, headache, fatigue

Dermatologic: Rash

Gastrointestinal: Nausea, vomiting, dyspepsia, diarrhea, abdominal pain, xerostomia, unpleasant taste

Hepatic: Increased ALT

Neuromuscular & skeletal: Arthritis, tremor

Respiratory: Cough, pharyngitis, rhinitis, bronchitis, upper respiratory infection, bronchospasm, increased sputum production

Ophthalmic solution:

>10:

Central nervous system: Headache (40%)

Gastrointestinal: Unpleasant taste

Ocular: Burning, irritation, stinging

Respiratory: Nasal congestion

1% to 10%:

Ocular: Conjunctivitis, eye redness, photophobia

Respiratory: Asthma, rhinitis


Stability

Store at 2°C to 30°C/36°F to 86°F; do not freeze


Mechanism of Action

Inhibits the activation of and mediator release from a variety of inflammatory cell types associated with asthma including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets; it inhibits the release of histamine, leukotrienes, and slow-reacting substance of anaphylaxis; it inhibits the development of early and late bronchoconstriction responses to inhaled antigen


Pharmacodynamics/Kinetics

Duration of therapeutic effect: 2 hours

Protein binding, plasma: 89%

Bioavailability: Systemic: 7% to 9% absorption

Half-life: 1.5-2 hours

Elimination: Excreted unchanged in urine


Usual Dosage

Inhalation: Children >12 years and Adults: 2 inhalations 4 times/day; may reduce dosage to 2-3 times/day once desired clinical response to initial dose is observed

Ophthalmic: 1-2 drops in each eye


Mental Health: Effects on Mental Status

May cause dizziness or drowsiness


Mental Health: Effects on Psychiatric Treatment

None reported


Dental Health: Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions


Dental Health: Effects on Dental Treatment

No effects or complications reported


Patient Information

Do not use during acute bronchospasm. Use exactly as directed; do not use more often than instructed or discontinue without consulting prescriber. You may experience drowsiness, dizziness, fatigue, especially during early therapy (use caution when driving or engaging in tasks requiring alertness until response to drug is known); dry mouth, nausea, or vomiting (small frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help). Report persistent runny nose, cough, cold symptoms; unresolved gastrointestinal effects; skin rash; joint pain or tremor; or if breathing difficulty persists or worsens. Breast-feeding precautions: Consult prescriber if breast-feeding.


Nursing Implications

Nedocromil is not a bronchodilator and, therefore, should not be used for reversal of acute bronchospasm; has no known therapeutic systemic activity when delivered by inhalation


Dosage Forms

Aerosol: 1.75 mg/activation (16.2 g)

Solution, ophthalmic: 2% (5 mL)


Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved